First a little explanation about the new unique product with its own delivery system. This is not only a medication but also a matchstick-sized osmotic mini pump that is the size of a match and is placed just beneath the skin to deliver a continuous and consistent flow of medication for a year.

Study announces a new benefit in addition to reductions in major adverse cardiovascular events.

Does liraglutide help in the reduction of cardiovascular diseases?

Alogliptin is efficient and safe in the management of type 2 diabetes even in patients who have cardiovascular disease as a comorbidity.

Is semaglutide a better way to manage type 2 diabetes?

Dr. Jovanovic discusses the safety of diabetes medications during pregnancy, and advocates that insulin is the only treatment that is truly safe.

Exclusive Interview from AACE Orlando This is a 5-part transcript. Part 1 | Part 2 | Part 3 | Part 4 | Part 5 Steve Freed: Well, it’s a real honor to be here at AACE 2016 at Orlando. And to be with probably the most knowledgeable person when it …

A new weight loss device, AspireAssist, offers a novel approach to cutting calories: draining them from the stomach before they are fully digested. The AspireAssist® system consists of a thin tube implanted in the stomach, connecting to an outside port on the skin of the belly.

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.